MedTrace Logo

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

NCT03984760 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2021-03-10

No results posted yet for this study

Summary

To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis

Conditions

Interventions

DRUG

Ferric Citrate

Take the capsules with meals or immediately after meals.

DRUG

Sevelamer Carbonate

Take the tablets with meals.

Sponsors & Collaborators

  • Shandong Weigao Panion Pharmaceutical Co. Ltd.

    collaborator UNKNOWN

  • Panion & BF Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Xiangmei Chen · The General Hospital of the People's Liberation Army (PLAGH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2021-02-20
Completion
2021-02-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984760 on ClinicalTrials.gov